SCNN1B as a Radioligand Therapy Target
SCNN1B, sodium channel epithelial 1 subunit beta, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SCNN1B staining is highest in skin cancer (100% of samples positive), head and neck cancer (100% of samples positive) and cervical cancer (83% of samples positive). Clinical status: Clinical-stage (up to phase 2, any modality).
Is SCNN1B a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in skin cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SCNN1B expression in cancer
Protein expression of SCNN1B across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Skin Cancer | 0.64 | High | 100% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Cervical Cancer | 0.47 | Medium | 83% |
| Thyroid Cancer | 0.42 | Medium | 100% |
| Bladder Cancer | 0.42 | Medium | 83% |
| Colorectal Cancer | 0.36 | Medium | 92% |
| Liver Cancer | 0.31 | Medium | 67% |
| Glioma | 0.30 | Medium | 82% |
| Gastric Cancer | 0.30 | Medium | 73% |
| Endometrial Cancer | 0.28 | Medium | 83% |
| Ovarian Cancer | 0.28 | Medium | 67% |
| Breast Cancer | 0.28 | Medium | 67% |
| Testicular Cancer | 0.27 | Medium | 73% |
| Neuroendocrine Tumors | 0.25 | Medium | 75% |
| Pancreatic Cancer | 0.22 | Medium | 67% |
| Melanoma | 0.22 | Medium | 50% |
| Lung Cancer | 0.22 | Medium | 50% |
| Lymphoma | 0.06 | Low | 17% |
| Prostate Cancer | 0.06 | Low | 17% |
| Kidney Cancer | 0.03 | Low | 8% |
Is SCNN1B internalized?
Nuclens has not yet extracted internalization evidence for SCNN1B. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SCNN1B clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for SCNN1B yet. Search ClinicalTrials.gov for SCNN1B trials.
SCNN1B normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SCNN1B in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SCNN1B gene essentiality (DepMap)
CRISPR knockout effect across 1239 cancer cell lines: 0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related skin cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · B7-H3 (CD276) · SSTR2 · ITGB6 · HER2 (ERBB2) · ITGAV
See all radioligand therapy targets in skin cancer.
See how SCNN1B ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.